Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel agents for treating diabetes disclosed in recent patent literature

Dec. 10, 2007

GSK patent claims new pharmaceutically acceptable salts of sildenafil

Dec. 10, 2007

Bayer Schering Pharma takes next step towards important oral contraceptive milestone

Dec. 7, 2007

Treatment effects and cardiovascular safety of dapoxetine assessed in phase III study

Dec. 7, 2007

Mirodenafil significantly improves erectile dysfunction in double-blind study

Dec. 7, 2007

FDA accepts Repros' proposal to initiate phase III studies of Proellex for uterine fibroids

Dec. 5, 2007

New therapeutic agents for metabolic disorders imparted in recent patents

Dec. 4, 2007

Modest weight loss seen with pharmacotherapy for obesity/overweight

Dec. 3, 2007

Pipex files NDA in U.S. for Coprexa in Wilson's disease

Nov. 30, 2007

Indevus reports positive results from phase II trial of octreotide implant for acromegaly

Nov. 30, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Roche secures CE mark for Alzheimer’s blood test
BioWorld
Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out amyloid pathology, a hallmark of...